These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9216640)

  • 1. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
    Cesano A; Visonneau S; Rovera G; Santoli D
    Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
    Cesano A; Visonneau S; Santoli D
    Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
    Visonneau S; Cesano A; Torosian MH; Santoli D
    Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
    Cesano A; Visonneau S; Santoli D
    Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.
    Iwanuma Y; Chen FA; Egilmez NK; Takita H; Bankert RB
    Cancer Res; 1997 Jul; 57(14):2937-42. PubMed ID: 9230205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
    Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
    Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction.
    Asselin-Paturel C; Megherat S; Vergnon I; Echchakir H; Dorothée G; Blesson S; Gay F; Mami-Chouaib F; Chouaib S
    Cancer; 2001 Jan; 91(1):113-22. PubMed ID: 11148567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
    Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
    In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice.
    Silver DF; Hempling RE; Piver MS; Repasky EA
    Gynecol Oncol; 2000 Jun; 77(3):377-82. PubMed ID: 10831345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.